HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech, Inc.

http://www.gene.com

Latest From Genentech, Inc.

US FDA’s Big Transition: Not The Commissioner – The Drug Center

It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.

FDA Leadership

High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

Deals Leadership

Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger

Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia

Deals M & A

Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals

Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals leads to removal of indications for two PD-1/L-1 inhibitors, AstraZeneca’s Imfinzi and Bristol-Myers Squibb’s Opdivo, both of which had failed confirmatory trials.

Review Pathway Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Tanox
UsernamePublicRestriction

Register